Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on November 6, 2023, primarily to report its financial results for the third quarter and the first nine months of 2023. The company issued a press release on November 6, 2023, detailing these results, which is incorporated by reference as Exhibit 99.1 to the filing. Investors should refer to this press release for the specific financial figures and operational performance details. This filing serves as the official notification of VRTX's financial performance for the period ending September 30, 2023. While the 8-K itself does not contain the detailed financial statements, it directs stakeholders to the accompanying press release for comprehensive information on revenue, earnings, and other key financial metrics. The filing also includes the necessary exhibits, notably the press release and the XBRL interactive data file.
Key Highlights
- 1Vertex Pharmaceuticals filed an 8-K on November 6, 2023, to report Q3 and year-to-date financial results.
- 2The detailed financial results are provided in a press release dated November 6, 2023, attached as Exhibit 99.1.
- 3The press release covers financial performance for the three and nine months ended September 30, 2023.
- 4This filing confirms the release of VRTX's Q3 2023 financial performance data.
- 5Information furnished under Item 2.02 is not considered 'filed' for liability purposes under Section 18 of the Exchange Act, but is incorporated by reference.
- 6The filing includes the Cover Page Interactive Data File in XBRL format.